We are live on ! Find out more
NAGE

Niagen Bioscience
NAGE

46 hedge funds and large institutions have $13.6M invested in Niagen Bioscience in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

1.15% more ownership

Funds ownership: 12.16% → 13.31% (+1.1%)

11% less capital invested

Capital invested by funds: $15.3M → $13.6M (-$1.69M)

12% less funds holding

Funds holding: 52 → 46 (-6)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Holders
46
Holders Change
-6
Holders Change %
-11.54%
% of All Funds
1.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
16
Reduced
12
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.45M
2
TCM
Tieton Capital Management
Washington
+$1.95M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$111K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$87.2K
5
Barclays
Barclays
United Kingdom
+$32K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$209K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$188K
3
NSIM
North Star Investment Management
Illinois
-$170K
4
Morgan Stanley
Morgan Stanley
New York
-$129K
5
Citigroup
Citigroup
New York
-$81.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFA
26
Nationwide Fund Advisors
Ohio
$50K – – –
AIG
27
American International Group
New York
$47K +$3.32K +1,170 +7%
LPL Financial
28
LPL Financial
California
$33K – – –
Bank of America
29
Bank of America
North Carolina
$33K +$10.2K +3,586 +42%
Barclays
30
Barclays
United Kingdom
$31K +$32K +11,293 +2,155%
MCM
31
MAI Capital Management
Ohio
$29K – – –
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$27K +$28.4K +10,002 New
New York State Common Retirement Fund
33
New York State Common Retirement Fund
New York
$20K +$3 +1 +0%
Deutsche Bank
34
Deutsche Bank
Germany
$18K -$31.4K -11,082 -61%
Legal & General Group
35
Legal & General Group
United Kingdom
$13K +$5.56K +1,962 +71%
PFO
36
Pathstone Family Office
New Jersey
$8K +$8.51K +3,000 New
AIP
37
Ameritas Investment Partners
Nebraska
$6K +$6.32K +2,230 New
AWM
38
Avior Wealth Management
Nebraska
$5K – – –
AIM
39
Acrospire Investment Management
Illinois
$5K +$5.42K +1,913 New
IWM
40
IHT Wealth Management
Illinois
$4K +$2.37K +834 +100%
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$3K -$3.02K -1,066 -49%
HS
42
Horan Securities
United States
$3K +$3.09K +1,090 New
MAM
43
Meeder Asset Management
Ohio
$2K – – –
AA
44
AlphaMark Advisors
Kentucky
$2K +$1.89K +667 New
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$683 -$805 -284 -53%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$188K -56,866 Closed
Citigroup
47
Citigroup
New York
– -$81.5K -28,723 -100%
US Bancorp
48
US Bancorp
Minnesota
– -$75K -22,634 Closed
RFC
49
Regions Financial Corp
Alabama
– -$55K -16,667 Closed
SCM
50
Silver Capital Management
New York
– -$45K -13,562 Closed
1
2
3

NAGE Hedge Fund Activity: Q1 2017 in Review

46 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2017, worth a combined $13.6M — down 11% from $15.3M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of NAGE and 7 opened new positions — a net loss of 2 holders — while 12 trimmed existing stakes and 16 added.

The largest buyer was BlackRock, adding an estimated $3.45M. The largest seller was Millennium Management, cutting an estimated $209K.

  • 46 institutional investors held Niagen Bioscience (NAGE) as of Q1 2017, down from 52 in Q4 2016.
  • Funds reported $13.6M of Niagen Bioscience stock for Q1 2017, down 11% quarter-over-quarter.
  • 7 funds opened new Niagen Bioscience positions in Q1 2017 and 9 closed out, a net change of -2 holders.
  • The largest Niagen Bioscience buyer in Q1 2017 was BlackRock, an estimated $3.45M added.
  • The largest Niagen Bioscience seller in Q1 2017 was Millennium Management, an estimated $209K sold.

Based on aggregated 13F filings for Q1 2017.